This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVOOrder ABRYSVOAccess & Support

Access & Support

Health Plan CoverageRequest a RepEventsMaterialsVideos
Prescribing InformationIndicationsPatient SiteMaternal
The CDC recommends offering RSV vaccination year-round to eligible older adults aged 60 and older who remain unvaccinated based on shared clinical decision-making1
Every breath they take matters
RSV won’t wait. Vaccinate today.
ABRYSVO®: CDC-recommended for protection against RSV in adults aged 60 years and older based on shared clinical decision-making2
View the Clinical Data Loading ReferencesEstimated based on average respiratory rates from birth to age 60.3-5 Rates of systemic AEs similar to placebo in older adults Kicker Header of this card goes here

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

View Safety Data Loading

Optional footnote area for disclaimers etc.

Similar rates of systemic AEs observed between ABRYSVO and placebo groups6†

View Safety Data Loading

†The most common solicited local and systemic adverse reactions (≥10%) were fatigue (15.5%), headache (12.8%), pain at the injection site (10.5%), and muscle pain (10.1%).6

Powerful protection against RSV in older adults

86% vaccine efficacy against RSV-LRTD with ≥3 symptoms (96.66% CI: 32.0, 98.7)6

67% vaccine efficacy against RSV-LRTD with ≥2 symptoms (96.66% CI: 28.8, 85.8)6

View Efficacy Data Additional Data

‡Interim data from season 1. The median duration of efficacy follow-up with 7 months. Evaluable efficacy population: ABRYSVO, n=16,306; placebo, n=16,308.6

Vaccinate your patients aged 60 years and older today with ABRYSVO6

Vaccine Locator Tool Loading
Approved for 2 Vulnerable Populations

The only RSV vaccine approved for both older adults aged 60 years and older and infants (from birth through 6 months) via maternal immunization (at 32-36 weeks of gestation)6

Learn more about the maternal indication

Loading
ABRYSVO Reconstitution

See Pfizer's convenient, needle-free§ reconstitution kit6
§Needle required for intramuscular injection is not included.

Loading
Resources and Access Info

Get the support you need and learn more about costs and coverage

Loading
ReferencesAE=adverse event; CDC=Centers for Disease Control and Prevention; LRTD=lower respiratory tract disease; MMWR=Morbidity and Mortality Weekly Report; RSV=respiratory syncytial virus.
Stay Informed
Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View Resources

Stay Informed
Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View Resources

References:Centers for Disease Control and Prevention. Healthcare providers: RSV vaccination for adults 60 years of age and over. August 30, 2023. Accessed December 22, 2023. https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html#vax-recMelgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801.Johns Hopkins Medicine. Vital signs (body temperature, pulse rate, respiration rate, blood pressure). Accessed August 22, 2023. https://www.hopkinsmedicine.org/health/conditions-and-diseases/vital-signs-body-temperature-pulse-rate-respiration-rate-blood-pressureUpToDate. Normal respiratory rate and heart rate in children. Accessed August 12, 2023. https://www.uptodate.com/contents/the-pediatric-physical-examination-general-principles-and-standard-measurements#H10Data on file. Pfizer Inc; August 2023.ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; August 2023.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-A1G-USA-0812
IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all vaccine recipients
  • In clinical trials with older adults, the most commonly reported (≥10%) adverse reactions were fatigue (15.5%), headache (12.8%), pain at the injection site (10.5%), and muscle pain (10.1%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO versus 4.4% placebo) and neonatal jaundice (7.2% ABRYSVO versus 6.7% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO.
IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
You are now leaving PfizerPro  
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367